

VALIRX PLC

("ValiRx", the "Company" or the "Group")

Result of General Meeting and Total Voting Rights

London, UK., 22 May 2020: ValiRx Plc (AIM: VAL), the clinical stage biotechnology company announces that, at the General Meeting of the Company held earlier today, all resolutions were duly passed.

The poll results are set out below:-

Resolutions	For	Against	Discretion
Resolution 1 (Ordinary) Allotment of share capital	1,994,665	39,045	2,031
Resolution 2 (Special) Dis-application of pre-emptive rights	1,968,954	66,423	2,040

As a consequence, further to the announcements of 4 May 2020 and of 6 May 2020, application has been made for the 18,069,467 new ordinary shares to be admitted to trading on AIM, which is expected to occur on or around 26 May 2020. There are no shares held in treasury. The 18,069,467 new ordinary shares will rank *pari passu* with the existing ordinary shares of ValiRx.

Following admission, the Company will have in issue 36,062,373 ordinary shares with voting rights. The above figure may be used by shareholders as the denominator for calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Disclosure and Transparency rules.

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

For more information, please contact:

ValiRx plc

Tel: +44 (0) 20 7073 2628

www.valirx.com

Kevin Alexander

Cairn Financial Advisers LLP (Nominated Adviser)

Tel: +44 (0) 20 7213 0880

Liam Murray / Jo Turner / Ludovico Lazzaretti

Peterhouse Capital Limited (Sole Broker)

Tel: +44 (0) 20 7469 0930

Duncan Vasey / Lucy Williams / Eran Zucker

Notes for Editors

About ValiRx

ValiRx is a biotechnology oncology focused company specialising in developing novel treatments for cancer and associated biomarkers. It aims to make a significant contribution in “precision” medicine and science, namely to engineer a breakthrough into human health and well-being, through the early detection of cancer and its therapeutic intervention.

The Company’s business model focuses on out-licensing therapeutic candidates early in the development process. By aiming for early-stage value creation, the company reduces risk considerably while increasing the potential for realising value. The group is already in licensing discussions with major players in the oncology field.

ValiRx’s two classes of drugs in development, which each have the potential for meeting hitherto unmet medical needs by existing methods, have worldwide patent filings and agreed commercial rights. They originate or derive from World class institutions, such as Cancer Research UK and Imperial College.

Until recently, cancer treatments relied on non-specific agents, such as chemotherapy. With the development of target-based agents, primed to attack cancer cells only, less toxic and more effective treatments are now possible. New drugs in this group—such as those in ValiRx’s pipeline—promise to greatly improve outcomes for cancer patients.

The Company listed on the AIM Market of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL.